Objective
to assess the efficacy and safety of a strategy of pre-treatment with ticagrelor compared to no pre-treatment and administration of ticagrelor or prasugrel after coronary angiography
Study
adaptive, open-label, multicentre randomised trial
Population
patients with NSTE-ACS and planned invasive strategy
Endpoints
composite cardiovascular death, MI, stroke and major or fatal bleeding (BARC 3,4,5) at 30 days
Conclusion
taken into consideration stopping the trial for futility and low event rates makes it unlikely that either an upstream or downstream strategy with P2Y12 inhibitors will be superior
Tarantini et al. J Am Coll Cardiol. 2020;76:2450-9